TEA TREE TREATISE

NZ Tea Tree Agribiz - A sunrise industry

The case for NZ mānuka and kānuka tea tree agribiz in the Far-North as a **sunrise industry** V kiwifruit, now a **sunset** industry.

Authors: “OpenAI" & N Iverson - Director
TRIBAL NATURAL HEALTHCARE LTD

Kaupapa of this Treatise

To present the case for an NZD16.6M agribiz sector project. One based not on introduced species but plants with biological exclusivity to Aotearoa / New Zealand with healthcare usage applications on a global scale.

(1) PART 1

Investment into **a sunrise industry,** the NZ Tea Tree agribiz sector.

- **Endemic** to Aotearoa/New Zealand.
- One structured on a low cost, for profit, "Business Combination" partnering model with immediate access to integrated value adding and foreign distribution.
- A model that delivers recurring income and wealth generation for "*Whānau-on the-Whenua*" taonga supply chain landowners on an intergenerational basis in compliance with the protocols of tikanga and kaitiakitanga.

(2) PART 2

Divestment out of **a sunset industry,** the NZ kiwifruit agribiz sector.

- **Not endemic** to Aotearoa/New Zealand.
- Once Zespri's patent and PVR protection expires globally, ***anyone*** **will be able to grow G3** without paying a license fee.
- This **removing** Zespri's most powerful competitive moats.
- Zespri's CEO has been reported as warning that the industry's **commercial advantage window is shrinking.**

PART 1

AN ANALYSIS OF THE FUTURE OF THE NZ TEA TREE AGRIBIZ INDUSTRY

Part 1

THE BOTTOM LINE

With strong emerging clinical data, inherent biological exclusivity, premium branding potential, and global demand for natural pathogen inhibitors, **NZ's mānuka and kānuka oil industry is poised to become a billion-dollar agribusiness within 10–15 years**.

Early movers will gain the largest market share and IP advantages.

Presented below is a comprehensive **investment case for expanding New Zealand's native tea tree (mānuka and kānuka) agribusiness sector**, focusing on their unique, gender-specific therapeutic oils.

---

1. Scientific Validation – The Breakthrough Catalyst

- **Clinical evidence emerging**: Trials have shown that **mānuka and kānuka tea tree oils** can inhibit or neutralize certain **malicious pathogens** (bacterial, fungal, viral).
- **Unique chemistry**:
  - *Mānuka oil* – high in **β-triketones** (i.e. leptospermone), giving antimicrobial properties.
  - *Kānuka oil* – rich in **α-pinene** (monoterpenes) and other sesquiterpenes, with anti-inflammatory and immune-modulating effects. Considered to be superior to Mānuka oil.
- **Therapeutic potential**: Beyond topical antimicrobial use, research indicates promise in wound care, dermatology, oral health, respiratory infection and nosocomial infection management.

---

2. Competitive Advantages for New Zealand

- **Endemic resource**: True mānuka (*Leptospermum Scoparium*) and kānuka (*Kunzea Ericoides / Robusta*) are native to NZ, giving the country a **biological monopoly** on the purest strains.
- **Terroir-driven potency**: Oils from specific NZ regions have higher active compound content than overseas equivalents.
- **IP & branding power**: Similar to how "Mānuka honey" in its earlier years, became a protected, high-value global brand, "NZ Native Tea Tree Oils" can be marketed as premium, origin-verified ingredients from a globally trusted provenance.

---

3. Market Trends & Growth Potential

- **Natural antimicrobials**: Rising antibiotic resistance is driving demand for plant-based alternatives.

- **Wellness & clean-label products**: Consumers prefer naturally derived, sustainable actives in cosmetics, personal care, and natural remedies.
- **Global infection control market**: Expected to exceed **USD500B by 2030**, with therapeutic oils for medicinal use being the fastest-growing segment.
- **Functional cosmeceuticals**: Oils can be positioned as both *active pharmaceutical ingredients* (APIs) and *cosmetic actives*.

---

4. Untapped Agribusiness Opportunity

- **Currently underdeveloped**: Large-scale mānuka/kānuka oil production is still niche compared to honey.
- **Gender-specific planting**: Since these species are dioecious (separate male and female plants), selective breeding can optimize oil yield and active composition, opening advanced horticultural R&D investment channels.
- **Agroforestry synergy**: Oils can be harvested alongside honey production or from marginal land, improving farm resilience and biodiversity.

---

5. Investment Drivers

- **Clinical credibility:** Scientific validation supports premium pricing.
- **High-value per ha:** Essential oils deliver significantly higher $/ha returns than many conventional crops.
- **Diversification:** Reduces over-reliance on dairy, meat, and low-margin horticulture.
- **Export leverage:** NZ can position itself as the *global leader* in native therapeutic oils, just as it has with mānuka honey.
- **Sustainability:** Native planting sequesters carbon, enhances pollinator health, and protects waterways.

---

6. Strategic Recommendations

- **Scale up cultivation** on marginal and erosion-prone land.
- **Invest in extraction infrastructure** near growing regions to reduce transport costs.
- **Develop vertical integration** – from raw oil production to finished therapeutic products.
- **Secure geographical indication (GI) protection** for "NZ Native Tea Tree Oil."
- **Build pharma partnerships** to fast-track clinical applications.

RESEARCH

CULTURAL / TRADITONAL USE

For more than 1,000 years the natives of New Zealand have used the oils for medicinal, therapeutic use on a gender specific basis. Manuka for the women (wahine) and kanuka for the male (warrior). NOT aromatherapy or beauty. This making them entrants in the infection control marketplace, reportedly a USD263B PA total addressable market. Ethnobotanical and aromatherapy texts record Māori uses of Leptospermum (mānuka) and Kunzea (kānuka) for wound care, poultices, inhalations and other medicinal applications; folklore references treat them as "female" and "male" trees respectively. These sources support the historical use is therapeutic/medicinal rather than purely "aromatherapy."
Salvatore Battaglia ScienceDirect

KEY POINTS

- Māori tradition **does** include folklore that treats **mānuka** and **kānuka** as different trees with gendered symbolic uses (manuka = female/wahine; kanuka = male/warrior) — this is recorded in ethnobotanical sources.
  Salvatore Battaglia ScienceDirect
- Modern lab studies show **mānuka and kānuka oils have measurable antimicrobial (antibacterial, antifungal, anti-inflammatory) activity** in vitro — so they are *plausible* entrants for infection-control / therapeutic applications beyond "aromatherapy." Clinical evidence is more limited and context-dependent.
  PMC Science Direct PubMed
- Market sizing depends heavily on how you define the target market: the **aromatherapy** market estimates vary (reports show figures from ~USD 2B to >USD 9B depending on scope and year), so the "USD 5–6B p.a." band is within the spread but not a single agreed number.
  Grand View ResearchGlobal Market Insights Inc.
- **Infection control / infection prevention** market estimates also vary widely by report and scope. Several reputable market reports (which include broad segments such as PPE, disinfectants, sterilization, diagnostics, coatings, etc.) put the market in the **hundreds of billions** (e.g. USD235B–266B for 2024–2025 by some trackers), this making our USD263B figure within the range of published forecasts. We noted that other research houses give smaller numbers depending on segmentation. In short: *it can be* a **USD100B–300B+** opportunity in a broad definition of the TAM.
  GlobeNewswire Precedence ResearchGrand View Research

1. **Antimicrobial science**
   - Systematic reviews and multiple in-vitro studies document antimicrobial (and anti-inflammatory) properties of mānuka and kānuka oils and extracts. Results are promising for topical/infectious-disease contexts (e.g., skin infections) but most evidence is preclinical or small in-vivo studies; robust clinical trials and safety/toxicity profiling (e.g., ototoxicity, dermal irritation) are still needed before broad infection-control use in regulated medical settings. PMC PubMed MDPI

2. **Market sizing: aromatherapy vs infection control**
    - **Aromatherapy:** different market research firms report different sizes; Grand View (2024) reports ~USD 9.2B (2024 est.), other firms report smaller numbers (USD2–5B) depending on scope and whether they include finished consumer products, spa services, etc. So "aromatherapy market = USD5–6B" is plausible but not definitive — depends on which report one accepts.
      Grand View ResearchGlobal Market Insights Inc.

    - **Infection control / infection prevention:** report estimates vary widely by included product categories. Some firms report ~USD 50–75B (narrow definitions focused on healthcare sterilization/consumables), while others that include broader segments (PPE, disinfectants, diagnostics, hospital infrastructure, surface coatings, etc.) report **~USD 235–266B** (2023–2025 figures) with multi-hundred-billion TAM forecasts. Our USD263B number lines up with several broad TAM estimates — so the figure we use in our presentations is defensible where the TAM is defined broadly.
      Grand View ResearchPrecedence Research

A DEFENSIBLE STRATEGY / Practical takeaway / commercial view

- **Culturally and scientifically, AI research concurs that we are right to push the framing away from "aromatherapy essential oils."** There's historical medicinal use and modern antimicrobial evidence — which means a commercial strategy targeting therapeutic or infection-control applications is more defensible than pigeonholing the oils as spa/aromatherapy products.
  PMC ScienceDirect

- **BUT** moving from an antimicrobial *ingredient* to an approved infection-control product is nontrivial for a number of reasons including interalia, (a) a need for consistent sourcing and chemistry (batch-to-batch variability can be high in natural oils), (b) standardized extraction, (c) toxicology/clinical studies, (d) regulatory approvals (medical device/drug/biocide routes vary by country). Once these steps are taken, we can you credibly address the large institutional infection-control budgets.
  ScienceDirect PubMed

GO TO MARKET

Presented below is a **"*Go-to-market / decision matrix*** that positions mānuka and kānuka oils for therapeutic and infection-control use, not aromatherapy.

1. Scientific Rationale

- Mānuka oil, (e.g. the β-triketone-rich chemotypes from New Zealand's North Island), shows **strong invitro antibacterial activity**—for instance, against *Listeria*, MRSA, VRE, and *Salmonella*—with MICs in the low microgram-per-milliliter range. PMC
- It also exhibits **antifungal and antiviral activity** (e.g. HSV-1/2) and is generally considered **safe and non-irritant** in cosmetic testing Encyclopedia.

2. Regulatory Pathways

- **FDA 510(k):** Mānuka-derived products can qualify as medical devices. For example, a wound dressing containing Manuka honey received 510(k) clearance under code FRO (Dressings, Wound, Drug) FDA Access Data.
- **Cosmetic Use:** Mānuka oil is already used in skincare and cosmeceuticals in the US and EU under accepted safety monographs (CAS, CTFA, EINECS) Encyclopedia.
- **For antimicrobial/infection-control claims**, stricter pathways apply (e.g. drugs, medical devices, or biocides depending on jurisdiction), requiring toxicity data and efficacy demonstrations.

3. Market Size & Segmentation

- **Infection-Control Market** varies by scope:
    - Narrow definition—sterilization, disinfectants, etc.: ~USD51B in 2024 and USD69B by 2029 (CAGR ~6.3%). PR Newswire Markets and Markets
    - Broader market view—incl. PPE, diagnostics, surface coatings, services: forecasts reach up to **USD 511 B by 2033** (CAGR ~7.8%). Market.usMarket.us Media
- **Antimicrobial Ingredients Market** (natural and synthetic) is more modest: ~USD7B in 2024, rising to USD8.6B by 2033 (CAGR ~2.3%). Global Growth Insights

Decision Matrix: Aromatherapy vs. Therapeutic/Infection-Control Pathways

Strategy	Target Market	Effort & Requirements	Market Size Estimate
Aromatherapy / Cosmetic	Spa, personal skincare	Minimal clinical data; standard cosmetic regs	**USD 5–6B** (consumer aromatherapy range)
Therapeutic Topicals	Wound care, OTC antiseptics	Clinical trials, toxicology, regulatory clearances	Small subset of Infection Control market **(USD5–10 B)**
Clinical Infection-Control	Hospitals, clinics, institutions	Full medical device or drug approval pathway	Larger infection-control market **(USD 50–70B)**
Broader Infection Prevention	Institutions + consumer markets	Scaling supply, regulatory complexity, validation	Up to **USD500B+** in broadest TAM view

OIL THERAPUTIC EFFICACY

Although to date, most research has been leveraged to mānuka oil, some early studies suggest that **kānuka oil** exhibits stronger antimicrobial activity than mānuka oil against certain pathogens.

What the research shows:

- **Kānuka oil (Kunzea Ericoides)** often contains different chemical profiles (higher in compounds like α-pinene, 1,8-cineole, and terpinen-4-ol) compared to mānuka oil (Leptospermum Scoparium), which has β-triketones as signature compounds.
- Several **in vitro studies** have demonstrated that kānuka oil can have **greater inhibitory effects** on some bacteria and fungi, including *Staphylococcus aureus* and *Candida albicans*, relative to mānuka oil. This may be due to the synergistic effects of its terpene-rich composition.
- However, the evidence base is still limited—mostly lab studies rather than large-scale clinical trials—and efficacy can vary depending on the pathogen strain, extraction method, and oil chemotype.
- From a commercial or therapeutic development perspective, this suggests that **kānuka oil could be a highly valuable candidate** for further research and product development targeting infection control or topical therapeutics.
- Quite clearly, development of a range of differing **combination formulations** leveraging complementary effects of both oils to cover a broader antimicrobial spectrum and/or reduce resistance risks is an ongoing requirement.

BUSINESS COMBINATION

BIOMASS / OIL PROCUREMENT

The entire biomass procurement and oil production supply chain is outsourced via a "Business Combination" of independent owner/operators at **(1)** the pre/post-harvest (to farm gate) and extraction **(2)** the factory for shipment to the value adding facility in AU where it is shipped to the US as TGA/FDA compliant, retail shelf ready, SKUs. Over 95% of the cost structure comprises fully variable costs that scale according to demand with no C-Suite costs.

NZ TEA TREE OIL PRODUCTION OPERATIONS - FAR NORTH - TAI TOKERAU PROVINCE						
Item	**Year 1**	**Year 2**	**Year 3**	**Year 4**	**Year 5**	**Year 10**
Hectares harvested	**111**	**278**	**417**	**556**	**694**	**1,389**
Total kgs	2,000	5,000	7,500	10,000	12,500	25,000
Transfer value per kg	600	615	630	646	662	749
Transfer Sales	**1,200,000**	**3,075,000**	**4,727,813**	**6,461,344**	**8,278,597**	**18,732,945**
Mulch-Other sales	0	0	0	0	0	0
TOTAL SALES	**1,200,000**	**3,075,000**	**4,727,813**	**6,461,344**	**8,278,597**	**18,732,945**
Deduct						
DIRECT COSTS	728,667	1,772,276	2,721,124	3,713,870	4,752,145	10,687,529
Direct Harvest costs to farm gate	293,333	445,875	685,533	936,895	1,200,397	2,716,277
Payroll burden	58,667	89,175	137,107	187,379	240,079	543,255
Energy (diesel-water)	30,000	45,601	70,111	95,819	122,768	277,801
Vehicle / Equip costs	40,000	100,000	150,000	200,000	250,000	500,000
Net Farm Gate Payment (FGP) landowner	306,667	1,091,625	1,678,373	2,293,777	2,938,902	6,650,195
INDIRECT COSTS	190,000	287,650	374,308	465,122	560,246	1,106,268
Extraction Management (EBOI)	100,000	103,000	106,090	109,273	112,551	130,477
Management Fee (TPL)	60,000	153,750	236,391	323,067	413,930	936,647
Other payroll burden costs	30,000	30,900	31,827	32,782	33,765	39,143
TOTAL PRODUCTION COSTS	**918,667**	**2,059,926**	**3,095,432**	**4,178,991**	**5,312,391**	**11,793,796**
	77%	67%	65%	65%	64%	63%
EXTRACTION OPS PROFIT	**281,333**	**1,015,074**	**1,632,381**	**2,282,352**	**2,966,205**	**6,939,148**
	23%	33%	35%	35%	36%	37%
DEDUCT						
Tiringa (Hapu Extraction Royalty)	50,000	130,000	202,500	280,000	362,500	850,000
Net extraction EBITDA - NZD	231,333	885,074	1,429,881	2,002,352	2,603,705	6,089,148

SALIENT POINTS – 10 YEAR SYNOPSIS:

Total Business Combination Payouts 95.547,820

Comprising the following payouts:

- Seed to farm gate operations/landowners 47,739,910
- Extraction / shipment operations 13,265,583
- Tiringa (local marae) 4.250,000
- Profit retention (to supply partners) 30,292,327

THE FIVE PILLARS (Biomass whenua access)

The abovesaid distributions accord with the five pillars as per below:

(1) Long Term TSA's (Taonga Supply Agreements)
(2) Equitable, grower approved farm gate payment structure.
(3) Product Profit Sharing.
(4) Tiringa.
(5) Equity Ownership.

PART 2

AN ANALYSIS OF THE FUTURE OF THE NZ KIWIFRUIT INDUSTRY

THE BOTTOM LINE

China is now producing more G3 gold kiwifruit than New Zealand, **albeit illegally**. This discrepancy poses ongoing challenges for Zespri in protecting its licensed variety and defending its intellectual property rights. The long-term investment fundamentals for G3 are deteriorating — with **profit compression likely long before the G3 patent termination in 2039**.

Here are the **main reasons an investor should no longer consider entering the NZ gold kiwifruit (G3 SunGold) industry**:

---

1. Rapidly Growing Illegal Production in China

- China now has over **8,300 ha** of *unlicensed* G3 plantings, producing ~40m trays annually — with projections to exceed NZ's licensed output within a decade.
- This creates **direct price competition** in key Asian markets and erodes the premium NZ fruit commands.

2. Weak Intellectual Property Enforcement Overseas

- Plant Variety Rights (PVR) are **difficult to enforce** in both China and other markets.
- Even with court wins, stopping illegal plantings has been slow and largely ineffective.

3. Patent & PVR Expiry Timeline

- NZ's PVR protection for G3 expires globally in **2031**. The G3 patent in **2039.**
- Without exclusivity, G3 will become a **commodity crop** — prices could collapse similar to the fate of Hayward green kiwifruit.

4. Market Saturation Risk

- NZ has rapidly expanded G3 production, but **global demand may not keep pace** with combined NZ and Chinese output.
- Oversupply will in all probability, trigger significant price drops as early as 2031.

5. Brand Dilution & Quality Confusion

- Chinese-grown G3 is already entering markets **mislabeled or marketed alongside NZ fruit**, making it harder to sustain a premium brand image.

6. Rising Input & Compliance Costs

- Labour shortages, increasing wage costs, phytosanitary compliance, and climate-related challenges (frost, storms, PSA disease risk) are **eroding margins**.

7. Long-Term Asset Risk

- Orchard valuations are **tied to G3's premium pricing and exclusivity**. If profitability outlook declines, land values in kiwifruit regions could be expected to drop sharply.

BOTTOM LINE FOR NZ GROWERS

Most recent available data indicates that China is now producing more illegally grown G3 (SunGold) gold kiwifruit than New Zealand is growing legally. After 2039, **Zespri's monopoly on G3 ends**, and New Zealand growers will face **open-market competition** from producers globally.

G3 Gold Kiwifruit Threat Timeline

Year	Key Event / Trend	Impact on NZ Growers
2025	Chinese illegal plantings ~8,300 ha, producing ~40m trays; NZ ~9,000 ha, ~190m trays forecast for 2025. Zespri taking limited legal action in China.	Price pressure in Asian markets where Chinese fruit competes directly. Some brand confusion. Impact still manageable because NZ volumes dominate premium export slots.
2026–2028	Chinese plantings likely exceed **10,000 ha**, closing in on NZ's total area. Output could reach **60–80m trays**.	More aggressive price competition in key markets. NZ premium margins start eroding; weaker returns to growers if global supply growth outpaces demand growth.
2029–2032	If enforcement remains weak, China may be producing **100m+ trays**, close to NZ output. G3 "brand dilution" accelerates.	NZ struggles to maintain SunGold's premium price advantage. Some growers may face profitability squeeze; orchard valuations could soften.
2033–2038	Last years of G3's **Plant Variety Rights (PVR) protection** in NZ. Chinese output potentially exceeds NZ production.	Royalties and licensing revenue under severe strain. Global price gap between NZ and Chinese fruit narrows further. Zespri may need to rely heavily on brand marketing to differentiate.
2039	**PVR expires globally** for G3 (NZ's exclusive rights end). Anyone can plant it without license fees.	NZ loses exclusive commercial control. G3 becomes a commodity. Zespri must seek to successfully replace it with a *new* premium variety (e.g., G4, G5, Red etc).
Post-2039	Without replacement variety adoption, G3 pricing will most likely fall to near-commodity levels, similar to what happened to Hayward green kiwifruit.	Major profitability drop unless growers have converted orchards to next-gen licensed varieties, (if any available) with fresh, legal protection.

China (unauthorized G3 plantings)
Zespri estimates that there are approximately 8,387 hectares of illegal SunGold (G3) plantings in China, producing around 40 million trays of fruit annually — with about 20 million trays meeting the premium Class 1 quality grade.

New Zealand (licensed G3 plantings)
In comparison, New Zealand legally grows SunGold on about 9,000 hectares under license from Zespri.

Given that China's unauthorized area (8,387 ha) is close to New Zealand's legal area (9,000 ha), and factoring in production volumes, China is now surpassing New Zealand in G3 gold kiwifruit production, despite it being illegal. A trend that longer term data supports, indicating that unauthorized plantings in China grew from 5,400 hectares in 2021 to over 7,850 hectares by 2023, while New Zealand's remains around 9,000 hectares.



KIWIFRUIT INDUSTRY RISKS

When Zespri's *G3* gold kiwifruit patent expires in 2039, the New Zealand kiwifruit industry is likely to face a significant and multifaceted disruption. Here's a realistic breakdown of what could happen:

---

1. End of G3 Patent = End of Monopoly on Premium Gold Kiwifruit

- **Zespri's Edge Gone**: The G3 variety (also known as "SunGold") has been the cornerstone of Zespri's dominance in the premium kiwifruit space globally. Once the patent lapses, *any grower in the world* can legally propagate and sell G3, including current illegal growers.
- **Market Flooding**: Chinese producers, who already grow more G3 than NZ illegally, will likely scale up production and export as soon as WTO restrictions are lifted post-patent. With fewer regulatory or IP barriers, they could move aggressively into Europe, Asia, and even Australasia.

---

2. China's Competitive Advantages Hit NZ Hard

- **Lower Production Costs**: Labour, land, and logistics are significantly cheaper in China. This means they can undercut New Zealand prices—perhaps by 30–50%—and still remain profitable.
- **Sheer Volume**: China's capacity to scale is unmatched. If even a fraction of its current illegal production enters the global market, NZ growers will be swamped.

---

3. NZ Export Prices and Grower Returns Plummet

- **Price Compression**: With G3 no longer unique to Zespri and consumers offered cheaper Chinese alternatives, the premium pricing NZ growers currently enjoy is unlikely to hold.
- **Grower Profits Squeezed**: New Zealand growers—already operating under higher costs—will face thinner margins or unprofitable seasons unless they cut costs or increase yields substantially.

---

4. Zespri's Global Brand May Survive — But Weakened

- **Zespri as a Brand vs. Patent Holder**: While Zespri will lose the patent, it still has strong brand equity in key markets (e.g., Japan, Europe). That could help it retain some loyal retail and wholesale customers—**if** it pivots to a branded, premium niche model like Zespri Gold "Reserve" or similar.
- **Value Shift**: The IP monopoly allowed Zespri to extract value from exclusivity. Without that, they'll need to compete on **brand quality, post-harvest handling, and trust**—harder to enforce when a product is no longer unique.

5. New Zealand Industry's Likely Strategic Responses

- **Develop New Patented Varieties**: New varieties (like G4, G5, G6 etc.) could provide a temporary reprieve. But it takes 10+ years to breed and commercialize a new cultivar successfully—and not all are market winners.
- **Tighter Supply Chain Control**: Zespri may try to license brand use only to select producers globally (like it already does in Italy and Japan). This would help defend its brand integrity but **may not stop the price race to the bottom.**
- **Geographic Diversification**: Zespri already grows kiwifruit in Italy, Korea, and Japan. That global footprint could soften the impact, but only marginally.

---

6. Worst-Case Scenarios

- **Mass Grower Exit in NZ**: If prices fall below breakeven for several years, small and mid-size growers in New Zealand may leave the industry or switch crops entirely.
- **Legal and Trade Disputes Escalate**: Even post-patent, Zespri might try to use trade laws, branding regulations, or phytosanitary rules to limit Chinese imports—but these tools are weak once IP protection ends.

In Summary:

When the G3 patent expires, the New Zealand kiwifruit industry will lose its most potent competitive advantage.

Unless the industry pivots—fast—to new patented varieties, deeper brand differentiation, or cost-effective production, **Chinese producers will overwhelm NZ growers on both price and volume**.

The premium margins of today will become a commodity battleground tomorrow.

SUGGESTIONS FOR KIWIFRUIT GROWERS

THE CHALLENGE:

Mindset shift: G3 is not the future. It's your bridge.

Growers may be growing a high-value crop today, but in ~14 years, **G3 (SunGold)** won't be protected anymore.

- **Chinese growers will legally export G3 globally at much lower prices**, crashing the premium market NZ growers have relied on.
- So the question is: **How do you protect your income and land value?**

WHAT GROWERS CAN DO — STARTING NOW

1. Don't Rely on G3 Forever

- **Treat G3 like a cash cow with an expiry date.**
- Maximise its return over the next decade (invest in canopy, yield, orchard health).
- **Don't invest in new G3 blocks** — you may not recoup your money.

---

2. Push Zespri to Deliver the Next Winner

- Ask: *What is the G3 successor? G4? G5?* Who's trialing it? When can I plant it?
- Get involved in **PVR trials** or **Zespri cultivar development** if you're eligible.
- Secure early rights to **next-gen varieties** with 10–20 years of protection.
- Don't wait for Zespri to save you — be early, be involved, and build leverage.

---

3. Diversify Within Kiwifruit

- If you can, **don't put all your orchard into G3**. Consider:
  - **Green (Hayward)**: Still strong in some markets and lower input costs.
  - **Organic conversion**: Harder to compete with on price, but more protected niche.
  - **New varieties**: Any chance to plant early access cultivars? Jump in.

---

4. Cut Production Costs Now

- **Prepare for a lower-margin future.**
- Invest in automation (robotic pruning, picking tech).
- Improve yield per hectare.
- Reduce water use, optimise fertigation — become lean and resilient.

The goal: Be one of the last growers standing when prices drop.

---

5. Brand Yourself (If You're Big Enough)

- If you have size or a niche (e.g. organic, regenerative, boutique), explore:
  - Selling direct (domestically or offshore via digital channels).
  - Partnering with non-Zespri marketers post-patent.
- Small % of growers will thrive this way — but only if the value story is built early.

---

6. Protect Land Value

- Over 14 years, **watch land prices and orchard conversion trends**.
- If margins shrink long-term, pivot land use (e.g. diversify to avocados, citrus, berries, agritourism).
- As land is a growers biggest asset — **don't let monoculture sink flexibility.**

---

7. Plan the Transition

- Work backward from 2039 (G3 patent expiry).
- Treat now–2030 as **"Profit & Position" years**.
- Treat 2030–2039 as **"Transition & Adaptation" years**.
- You have time — but not forever.

In a Nutshell:

As a grower, focus should be on **profitability today + planting for tomorrow**.

G3 was a gift — but it's a gift that expires.

Growers should use the next decade to reposition their orchards and business so that they are not vulnerable when that global flood hits.

KIWIFRUIT PLANT VARIETY RIGHTS (PVR)

- Zespri secured PVR protection in New Zealand (and other countries, including China) for the G3 and G9 gold kiwifruit varieties. Those rights are set to expire in **2031**.

- This aligns with legal coverage under New Zealand's Plant Variety Rights Act.

Once the PVR expires in 2031, G3 becomes public domain under that legal regime—meaning growers would no longer require a license from Zespri to propagate or sell it in New Zealand (and potentially in other jurisdictions, depending on their laws). After that date, global growers could legally cultivate G3 free of that specific IP constraint.

1. Plant Variety Rights (PVR) — Expires 2031

- Zespri's PVR for the G3 variety covers New Zealand (and select other countries) and is set to expire in **2031.**
- After that date, growers in jurisdictions where these rights are in force (like New Zealand) won't need a license to propagate or sell G3.

2. Exclusive Licensing and Commercial Protection — Extends to 2039

Beyond PVR, Zespri controls commercial access through its licensing system. This includes limited allocations and tender-based licensing, which fosters exclusivity and premium value for growers—effectively extending the benefit of IP control until **September 6, 2039**.

Summary Table

Protection Type	What It Means	Expiry Date
PVR Protection	Legal exclusivity to propagate G3 in NZ (and certain jurisdictions)	**2031**
Commercial Licensing Exclusivity	Controlled release of planting rights via Zespri, maintaining global value	**2039 (Sep 6)**

IN SUMMARY

- **PVR (Plant Variety Right):** Ends in **2031** — allows anyone to grow G3 without legal restriction.
- **Zespri's Commercial Licensing Exclusivity:** Ends in **September 2039** — currently controls who can grow and sell G3 via legal contracts.

After that, **Zespri no longer has exclusive control** over:

- Who can grow G3.
- Where it can be grown
- Who can sell it under any name other than trademarked names/brands.

What Does This Mean for NZ Growers?

1. No More Licensing Fees
Growers won't need to pay Zespri huge sums for G3 licenses (currently ~$400k–600k/ha). That's a cost saving—but also removes a barrier for global competition.

2. Increased Global Competition

After 2039:

- **Anyone in the world** can legally grow G3 (SunGold) kiwifruit, including Chinese producers who have already planted thousands of hectares.
- Prices could drop if **supply increases faster than demand**, especially from low-cost producers (e.g., China, Chile, or even Europe).
- This is the big risk: global oversupply, leading to **price erosion.**
- This **threatening** the commercial viability of G3 as an industry in NZ.

THE BIG QUESTION?

Will there be replacement cultivars that will deliver the "security" that NZ growers have enjoyed since the rollout of the highly successful G3 cultivar launched in 2012 in the wake of PSA outbreak?

At this point in time. nobody knows.